Literature DB >> 25166046

Bone disease in hypoparathyroidism.

Bart L Clarke1.   

Abstract

Hypoparathyroidism is a rare disorder that may be acquired or inherited. Postsurgical hypoparathyroidism is responsible for the majority of acquired hypoparathyroidism. Bone disease occurs in hypoparathyroidism due to markedly reduced bone remodeling due to the absence or low levels of parathyroid hormone. Chronically reduced bone turnover in patients with hypoparathyroidism typically leads to higher bone mass than in age- and sex-matched controls. Whether this increased bone density reduces fracture risk is less certain, because while increased bone mineralization may be associated with increased brittleness of bone, this does not appear to be the case in hypoparathyroidism. Treatment of hypoparathyroidism with recombinant parathyroid hormone may reduce bone mineral density but simultaneously strengthen the mechanical properties of bone.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25166046     DOI: 10.1590/0004-2730000003399

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  4 in total

1.  PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization.

Authors:  Barbara M Misof; Paul Roschger; David W Dempster; Hua Zhou; John P Bilezikian; Klaus Klaushofer; Mishaela R Rubin
Journal:  J Bone Miner Res       Date:  2015-07-28       Impact factor: 6.741

Review 2.  Bone imaging in hypoparathyroidism.

Authors:  B C Silva; M R Rubin; N E Cusano; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-08-30       Impact factor: 4.507

3.  The Russian Registry of Chronic Hypoparathyroidism.

Authors:  Elena V Kovaleva; Anna K Eremkina; Alina R Elfimova; Julia A Krupinova; Ekaterina E Bibik; Irina S Maganeva; Anna M Gorbacheva; Ekaterina A Dobreva; Galina A Melnichenko; Natalia G Mokrysheva
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-16       Impact factor: 5.555

Review 4.  The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases.

Authors:  Janak L Pathak; Nathalie Bravenboer; Jenneke Klein-Nulend
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-08       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.